Q4 2015 13F Holders as of 31 Dec 2015
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
20,810,197
-
Share change
-
+5,648,248
-
Total reported value
-
$250,066,000
-
Price per share
-
$12.06
-
Number of holders
-
48
-
Value change
-
+$67,529,076
-
Number of buys
-
39
-
Number of sells
-
15
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q4 2015
As of 31 Dec 2015,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,810,197 shares.
The largest 10 holders included
FMR LLC, Capital World Investors, Foresite Capital Management II, LLC, ADAGE CAPITAL PARTNERS GP LLC, Rock Springs Capital Management LP, FIL Ltd, QVT Financial LP, WELLINGTON MANAGEMENT GROUP LLP, JENNISON ASSOCIATES LLC, and ORBIMED ADVISORS LLC.
This page lists
48
institutional shareholders reporting positions in this security
for the Q4 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.